Ask about this productRelated genes to: PSG3 Blocking Peptide
- Gene:
- PSG3 NIH gene
- Name:
- pregnancy specific beta-1-glycoprotein 3
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-09-13
- Date modifiied:
- 2015-09-07
Related products to: PSG3 Blocking Peptide
Related articles to: PSG3 Blocking Peptide
- CRISPR/Cas12a-powered biosensors with guanine (G)-rich sequence reporters (e.g., G-quadruplex and G-triplex) are widely used in detection applications due to their simplicity and sensitivity. However, when these biosensors are employed for molecular detection in complex samples, they may encounter difficulties such as high background signal and susceptibility to interference because of the "turn-off" signal output. Herein, we explore, for the first time, a set of phosphorothioate (ps)-modified G-quadruplex (G4) and G-triplex (G3) sequences that can bind with thioflavin T (ThT) in an active split CRISPR/Cas12a system (SCas12a) to generate a "turn-on" fluorescent signal. To apply this new phenomenon, we develop a universal SCas12a-powered biosensor for "turn-on" fluorescent detection of nucleic acid (miRNA-21) and non-nucleic acid (kanamycin) targets by using ps-modified hairpin G3 as a reporter (SCas12a/psHG3). Target recognition activates SCas12a's -cleavage activity, leading to cleavage at the loop region of the psHG3 reporter. The released prelocked psG3 DNA binds ThT to produce a strong fluorescence signal. Without preamplification, this strategy can detect miRNA-21 with a detection limit of 100 fM. Moreover, the SCas12a/psHG3 system was further utilized for detecting kanamycin by incorporating its aptamers, enabling the detection of kanamycin at concentrations as low as 100 pM. This work is the first to develop a "turn-on" SCas12a/psHG3 system, showcasing its improved performance and wide range of applications in synthetic biology-based sensing technology. - Source: PubMed
Publication date: 2025/04/24
Shi KaiLuo WenjieCheng YingLi HongleiPeng LiaiLuo XiangruiHu YuZhang JiahengChen Jiaxuan - Recently, the mRNA presence of pregnancy-specific glycoproteins (PSGs) in cancer biopsies has been shown to be associated with poor survival. Given the pregnancy-related function of PSGs, we hypothesized that PSGs might act in a sex-dependent behavior in cancer patients. A differential sex effect of PSG genes with respect to tumor immune landscape and cancer outcomes was investigated using statistical, bioinformatic, and machine learning analyses in The Cancer Genome Atlas (TCGA) data. The resulting findings were then validated in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) data. In a pan-cancer TCGA data analysis, the strongest PSG-related sex difference for the prognostic association was found in lung adenocarcinoma (LUAD). Kaplan-Meier analysis revealed that expression of PSG genes is strongly associated with overall survival rate in the female group on the TCGA, but not in the male group. This sex-specific association was validated in an independent dataset from the CPTAC study. A combination of PSG3, PSG7, and PSG8 expression was most significantly linked to poor prognosis in females (P = 8.67E-06 in TCGA and P = .0382 in CPTAC). Pathway analysis revealed enrichment of the 'KRAS Signaling Down' pathway in the high-risk female group. A predictive model showed good predictive performance for the female group (validated C-index = 0.78 in CPTAC), but poor predictive performance for the male group. These findings suggest that PSGs may have a sex-specific negative impact on survival in female LUAD patients, and the mechanism may be related to KRAS signaling pathway modulation. - Source: PubMed
Oh Jung HunRizzuto GabrielleElkin RenaWeistuch CoreyNorton LarryDveksler GabrielaDeasy Joseph O - (1) Background: Home sleep apnea testing, known as polysomnography type 3 (PSG3), underestimates respiratory events in comparison with in-laboratory polysomnography type 1 (PSG1). Without head electrodes for scoring sleep and arousal, in a home environment, patients feel unfettered and move their bodies more naturally. Adopting a natural position may decrease obstructive sleep apnea (OSA) severity in PSG3, independently of missing hypopneas associated with arousals. (2) Methods: Patients with suspected OSA performed PSG1 and PSG3 in a randomized sequence. We performed an additional analysis, called reduced polysomnography, in which we blindly reassessed all PSG1 tests to remove electroencephalographic electrodes, electrooculogram, and surface electromyography data to estimate the impact of not scoring sleep and arousal-based hypopneas on the test results. A difference of 15 or more in the apnea-hypopnea index (AHI) between tests was deemed clinically relevant. We compared the group of patients with and without clinically relevant differences between lab and home tests (3) Results: As expected, by not scoring sleep, there was a decrease in OSA severity in the lab test, similar to the home test results. The group of patients with clinically relevant differences between lab and home tests presented more severe OSA in the lab compared to the other group (mean AHI, 42.5 vs. 20.2 events/h, = 0.002), and this difference disappeared in the home test. There was no difference between groups in the shift of OSA severity by abolishing sleep scoring in the lab. However, by comparing lab and home tests, there were greater variations in supine AHI and time spent in the supine position in the group with a clinically relevant difference, either with or without scoring sleep, showing an impact of the site of the test on body position during sleep. These variations presented as a marked increase or decrease in supine outcomes according to the site of the test, with no particular trend. (4) Conclusions: In-lab polysomnography may artificially increase OSA severity in a subset of patients by inducing marked changes in body position compared to home tests. The location of the sleep test seems to interfere with the evaluation of patients with more severe OSA. - Source: PubMed
Publication date: 2024/04/27
Teixeira Raquel Chartuni PereiraCahali Michel Burihan - To evaluate combinations of candidate biomarkers to develop a multiplexed prediction model for identifying the viability and location of an early pregnancy. In this study, we assessed 24 biomarkers with multiple machine learning-based methodologies to assess if multiplexed biomarkers may improve the diagnosis of normal and abnormal early pregnancies. - Source: PubMed
Publication date: 2024/04/26
Barnhart Kurt TBollig Kassie JSenapati SuneetaTakacs PeterRobins Jared CHaisenleder Daniel JBeer Lynn ASavaris Ricardo FKoelper Nathanael CSpeicher David WChittams JesseBao JingxuanWen ZixuanFeng YanboKim MansuMumford SunniShen LiGimotty Phyllis - Regarding the extensive global attention to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that constitutes an international public health emergency, pseudovirus neutralization assays have been widely applied due to their advantages of being able to be conducted in biosafety level 2 laboratories and having a high safety factor. In this study, by adding a blue fluorescent protein (AmCyan) gene to the HIV system pSG3-△env backbone plasmid I and truncating the C-terminal 21 amino acids of the SARS-CoV-2 spike protein (S), high-titer SARS-CoV-2-Sdel21-AmCyan fluorescent pseudovirus was successfully packaged. The fluorescent pseudovirus was used to establish a neutralization assay in a 96-well plate using 293T cells stably transfected with the AF cells. Then, parameters such as the ratio of backbone and membrane plasmid, sensitive cells, inoculation of cells and virus, as well as incubation and detection time were optimized. The pseudovirus neutralization assay demonstrated high accuracy, sensitivity, repeatability, and a strong correlation with the luminescent pseudovirus neutralization assay. Additionally, we scaled up the neutralizing antibody determination method by increasing the plate size from 96 wells to 384 wells. We have established a robust fluorescent pseudotyped virus neutralization assay for SARS-CoV-2 using the HIV system, providing a foundation for serum neutralization antibody detection, monoclonal antibody screening, and vaccine development. - Source: PubMed
Publication date: 2024/03/22
Liang ZitengTong JinchengWu XiLiu ShuoWu JiajingYu YuanlingZhang LiZhao ChenyanLu QiongNie JianhuiHuang WeijinWang Youchun